Daiichi Sankyo Company, Limited · TSE:4568
Daiichi Sankyo — Q1 FY2012 Earnings Presentation
11 slides from Daiichi Sankyo's earnings presentation, Jul 31, 2012
Slide 1: Results Briefing
Results Briefing Results for Q1 FY2012 (April 1 - June 30, 2012) Tuesday, July 31, 2012 2:45pm ~ 3:40pm Manabu Sakai Senior Executive Officer, Head of Corporate Management Division
Slide 2: Financial Overview
Financial Overview O Daiichi-Sankyo
Slide 3: Overview of FY2012 Q1 Results
Overview of FY2012 Q1 Results - compared with FY2011 Q1 results - Consolidated Income Statement Ranbaxy Group Note : Figures of Ranbaxy are pre-adjusted before consolidation FY2011 FY2012 FY2012 FY2011 FY2012 FY2012 (Jan-Dec) Q1 Q1 (Jan-Mar) (Jan-Mar) Results Results Forecast Progress Results Result
Slide 4: Net Sales factors
Overview of FY2012 Q1 Results - compared with FY2011 Q1 results - JPY Bn 200 210 220 230 240 250 260 FY2011 Q1 Results 231.7 Japan Japan 5.5 ・New products: Memary +2.9, Nexium +1.7, Ranmark +0.6 ・Current products: Japan Impact of Olmetec, Rezaltas, Calblock -1.5 -7.8 NHI Price Cut Net Sales factors
Slide 5: Operating Income factors
Overview of FY2012 Q1 Results - compared with FY2011 Q1 results - JPY Bn 0 10 20 30 40 50 FY2011 Q1 Results 43.5 Operating Income factors Japan Japan (Incl.DSHC) -6.0 ・ Enhanced promotion of new products ・ Negative impact on NHI price cut Global business ・Increase factors: Global Business 8.0 DSI (I
Slide 6: Ordinary Income and Net Income factors
Overview of FY2012 Q1 Results - compared with FY2011 Q1 results - JPY Bn 0 10 20 30 40 50 Ordinary Income factors FY2011 Q1 Results 44.8 Operating Income -11.0 Non-operating Income 5.8 Non-operating income/expenses ・Increases in forex gains and gain on Non-operating Expenses valuation of derivatives
Slide 7: Sales of Major Products
Sales of Major Products JPY Bn FY2011 FY2012 FY2012 Prasugrel Global Sales Q1 Q1 Results Results Forecast Progress Olmesartan 63.3 60.0 237.0 25% Mil. US$ Global 120 115.8 Prasugrel 2.2 3.3 - - 111.0 (alliance revenue) Loxonin 14.4 14.1 62.0 23% 100 90.9 Cravit 8.4 8.1 37.0 22% 83.5 80 Nexium - 1.7
Slide 8: Major R&D Pipeline
Major R&D Pipeline Therapeutic area Phase 1 Phase 2 Phase 3 Application ■ CS-3150 (Anti-hypertensive) ■ CS-747 (US) ■ DU-176b (Global) (Prasugrel / Sickle cell disease (Edoxaban / AF / oral factor Xa inhibitor) ■ DS-7309 (Anti-diabetes) / anti-platelet agent) ■ DU-176b (Global) ■ DS-7250 (Anti-diabe
Slide 9: Schedule
Schedule 2012 August Thursday, August 9 Ranbaxy; Announcement of Financial Results for Q2 2012 Sunday, August 26 Prasugrel; Data announcement of TRILOGY ACS study in patient with ACS September without revascularization to be October presented at ESC Announcement of Wednesday, October 31 Financial Re
Slide 10: Memo
Memo 10
Slide 11: Daiichi Sankyo Co., Ltd. Corporate Communications Department
Contact address regarding this material Daiichi Sankyo Co., Ltd. Corporate Communications Department TEL: +81-3-6225-1126 Each numerical value regarding the future prospect in this material is derived from our judgment and assumptions based on the currently available information and may include risk
Daiichi Sankyo Company — Q1 FY2012 Earnings Presentation on 6ix